{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:50Z","timestamp":1790951450550,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74438-w","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:02:18Z","timestamp":1729846938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Designing a multi-epitope influenza vaccine: an immunoinformatics approach"],"prefix":"10.1038","volume":"14","author":[{"given":"Leila","family":"Momajadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khanahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Mahnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"74438_CR1","doi-asserted-by":"crossref","unstructured":"1. Cox, R. J., Brokstad, K. A. & Ogra, P. Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines. Scand. J. Immunol. 59, 1\u201315 (2004).","DOI":"10.1111\/j.0300-9475.2004.01382.x"},{"key":"74438_CR2","unstructured":"2. Influenza (Seasonal). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"74438_CR3","doi-asserted-by":"crossref","unstructured":"3. Amorij, J.-P., Huckriede, A., Wilschut, J., Frijlink, H. W. & Hinrichs, W. L. J. Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities. Pharm. Res. 25, 1256 (2008).","DOI":"10.1007\/s11095-008-9559-6"},{"key":"74438_CR4","doi-asserted-by":"crossref","unstructured":"4. Treanor, J. J. Influenza Vaccination. N. Engl. J. Med. 375, 1261\u20131268 (2016).","DOI":"10.1056\/NEJMcp1512870"},{"key":"74438_CR5","doi-asserted-by":"crossref","unstructured":"5. Ben-Yedidia, T. & Arnon, R. Epitope-based vaccine against influenza. Expert Rev. Vaccines. 6, 939\u2013948 (2007).","DOI":"10.1586\/14760584.6.6.939"},{"key":"74438_CR6","doi-asserted-by":"crossref","unstructured":"6. Bouvier, N. M. & Palese, P. The biology of influenza viruses. Vaccine. 26, D49\u2013D53 (2008).","DOI":"10.1016\/j.vaccine.2008.07.039"},{"key":"74438_CR7","doi-asserted-by":"crossref","unstructured":"7. Parrish, C. R. & Kawaoka, Y. The origins of new pandemic viruses: The Acquisition of New Host Ranges by Canine Parvovirus and Influenza A Viruses. Annu. Rev. Microbiol. 59, 553\u2013586 (2005).","DOI":"10.1146\/annurev.micro.59.030804.121059"},{"key":"74438_CR8","unstructured":"8. CDC. Types of Influenza Viruses. Centers for Disease Control and Prevention https:\/\/www.cdc.gov\/flu\/about\/viruses\/types.htm (2023)."},{"key":"74438_CR9","doi-asserted-by":"crossref","unstructured":"9. Medina, R. A. & Garc\u00eda-Sastre, A. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9, 590\u2013603 (2011).","DOI":"10.1038\/nrmicro2613"},{"key":"74438_CR10","doi-asserted-by":"crossref","unstructured":"10. Gerdil, C. The annual production cycle for influenza vaccine. Vaccine. 21, 1776\u20131779 (2003).","DOI":"10.1016\/S0264-410X(03)00071-9"},{"key":"74438_CR11","doi-asserted-by":"crossref","unstructured":"11. Valenciano, M. et al. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009\u20132010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLOS Med. 8, e1000388 (2011).","DOI":"10.1371\/journal.pmed.1000388"},{"key":"74438_CR12","doi-asserted-by":"crossref","unstructured":"12. Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. U. S. A. 111, 125\u2013130 (2014).","DOI":"10.1073\/pnas.1308701110"},{"key":"74438_CR13","doi-asserted-by":"crossref","unstructured":"13. Mora, M., Veggi, D., Santini, L., Pizza, M. & Rappuoli, R. Reverse vaccinology. Drug Discov. Today. 8, 459\u2013464 (2003).","DOI":"10.1016\/S1359-6446(03)02689-8"},{"key":"74438_CR14","doi-asserted-by":"crossref","unstructured":"14. Rawal, K. et al. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci. Rep. 11, 17626 (2021).","DOI":"10.1038\/s41598-021-96863-x"},{"key":"74438_CR15","doi-asserted-by":"crossref","unstructured":"15. Khalid, H. & Ashfaq, U. A. Exploring HCV genome to construct multi-epitope based subunit vaccine to battle HCV infection: Immunoinformatics based approach. J. Biomed. Inform. 108, 103498 (2020).","DOI":"10.1016\/j.jbi.2020.103498"},{"key":"74438_CR16","doi-asserted-by":"crossref","unstructured":"16. De Filette, M. et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine. 26, 6503\u20136507 (2008).","DOI":"10.1016\/j.vaccine.2008.09.038"},{"key":"74438_CR17","doi-asserted-by":"crossref","unstructured":"17. Neirynck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157\u20131163 (1999).","DOI":"10.1038\/13484"},{"key":"74438_CR18","doi-asserted-by":"crossref","unstructured":"18. Sanami, S. et al. Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches. Sci. Rep. 11, 12397 (2021).","DOI":"10.1038\/s41598-021-91997-4"},{"key":"74438_CR19","doi-asserted-by":"crossref","unstructured":"19. Singh, A., Thakur, M., Sharma, L. K. & Chandra, K. Designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci. Rep. 10, 16219 (2020).","DOI":"10.1038\/s41598-020-73371-y"},{"key":"74438_CR20","doi-asserted-by":"crossref","unstructured":"20. Eliasson, D. G. et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine. 29, 3951\u20133961 (2011).","DOI":"10.1016\/j.vaccine.2011.03.090"},{"key":"74438_CR21","doi-asserted-by":"crossref","unstructured":"21. Eliasson, D. G. et al. CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine. 26, 1243\u20131252 (2008).","DOI":"10.1016\/j.vaccine.2007.12.027"},{"key":"74438_CR22","doi-asserted-by":"crossref","unstructured":"22. Nain, Z., Karim, M. M., Sen, M. K. & Adhikari, U. K. Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans\u2014An integrated vaccinomics approach. Mol. Immunol. 120, 146\u2013163 (2020).","DOI":"10.1016\/j.molimm.2020.02.009"},{"key":"74438_CR23","doi-asserted-by":"crossref","unstructured":"23. Reese, K. A. et al. A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens. Vet. Med. Int. 2013, 316926 (2013).","DOI":"10.1155\/2013\/316926"},{"key":"74438_CR24","doi-asserted-by":"crossref","unstructured":"24. Hashemi, H. et al. Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus Challenge. PLoS ONE. 7, e45765 (2012).","DOI":"10.1371\/journal.pone.0045765"},{"key":"74438_CR25","doi-asserted-by":"crossref","unstructured":"25. Deng, L. et al. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. PLoS ONE. 10, e0126650 (2015).","DOI":"10.1371\/journal.pone.0126650"},{"key":"74438_CR26","doi-asserted-by":"crossref","unstructured":"26. Gonz\u00e1lez-Mora, A., Hern\u00e1ndez-P\u00e9rez, J., Iqbal, H. M. N., Rito-Palomares, M. & Benavides, J. Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery. Vaccines. 8, 504 (2020).","DOI":"10.3390\/vaccines8030504"},{"key":"74438_CR27","doi-asserted-by":"crossref","unstructured":"27. Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228, 1315\u20131317 (1985).","DOI":"10.1126\/science.4001944"},{"key":"74438_CR28","doi-asserted-by":"crossref","unstructured":"28. Marvin, D. A., Hale, R. D., Nave, C. & Helmer-Citterich, M. Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe. J. Mol. Biol. 235, 260\u2013286 (1994).","DOI":"10.1016\/S0022-2836(05)80032-4"},{"key":"74438_CR29","doi-asserted-by":"crossref","unstructured":"29. Scott, J. K. & Smith, G. P. Searching for peptide ligands with an epitope library. Science. 249, 386\u2013390 (1990).","DOI":"10.1126\/science.1696028"},{"key":"74438_CR30","doi-asserted-by":"crossref","unstructured":"30. Nicastro, J., Sheldon, K. & Slavcev, R. A. Bacteriophage lambda display systems: developments and applications. Appl. Microbiol. Biotechnol. 98, 2853\u20132866 (2014).","DOI":"10.1007\/s00253-014-5521-1"},{"key":"74438_CR31","doi-asserted-by":"crossref","unstructured":"31. Samoylova, T. I. et al. Infective and inactivated filamentous phage as carriers for immunogenic peptides. J. Virol. Methods. 183, 63\u201368 (2012).","DOI":"10.1016\/j.jviromet.2012.03.032"},{"key":"74438_CR32","doi-asserted-by":"crossref","unstructured":"32. Salmond, G. P. C. & Fineran, P. C. A century of the phage: past, present and future. Nat. Rev. Microbiol. 13, 777\u2013786 (2015).","DOI":"10.1038\/nrmicro3564"},{"key":"74438_CR33","doi-asserted-by":"crossref","unstructured":"33. Loc-Carrillo, C. & Abedon, S. T. Pros and cons of phage therapy. Bacteriophage. 1, 111\u2013114 (2011).","DOI":"10.4161\/bact.1.2.14590"},{"key":"74438_CR34","doi-asserted-by":"crossref","unstructured":"34. Prisco, A. & De Berardinis, P. Filamentous Bacteriophage Fd as an Antigen Delivery System in Vaccination. Int. J. Mol. Sci. 13, 5179\u20135194 (2012).","DOI":"10.3390\/ijms13045179"},{"key":"74438_CR35","doi-asserted-by":"crossref","unstructured":"35. Lavie, V. et al. EFRH\u2013Phage Immunization of Alzheimer\u2019s Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials. J. Mol. Neurosci. 24, 105\u2013114 (2004).","DOI":"10.1385\/JMN:24:1:105"},{"key":"74438_CR36","doi-asserted-by":"crossref","unstructured":"36. Aghebati-Maleki, L. et al. Phage display as a promising approach for vaccine development. J. Biomed. Sci. 23, 66 (2016).","DOI":"10.1186\/s12929-016-0285-9"},{"key":"74438_CR37","doi-asserted-by":"crossref","unstructured":"37. di Marzo Veronese, F., Willis, A. E., Boyer-Thompson, C., Appella, E. & Perham, R. N. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120. J. Mol. Biol. 243, 167\u2013172 (1994).","DOI":"10.1006\/jmbi.1994.1643"},{"key":"74438_CR38","doi-asserted-by":"crossref","unstructured":"38. van Houten, N. E., Zwick, M. B., Menendez, A. & Scott, J. K. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine. 24, 4188\u20134200 (2006).","DOI":"10.1016\/j.vaccine.2006.01.001"},{"key":"74438_CR39","doi-asserted-by":"crossref","unstructured":"39. Yip, Y. L., Smith, G. & Ward, R. L. Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunisation in Balb\/c mice. Immunol. Lett. 79, 197\u2013202 (2001).","DOI":"10.1016\/S0165-2478(01)00281-4"},{"key":"74438_CR40","doi-asserted-by":"crossref","unstructured":"40. Saha, S. & Raghava, G. P. S. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 65, 40\u201348 (2006).","DOI":"10.1002\/prot.21078"},{"key":"74438_CR41","doi-asserted-by":"publisher","unstructured":"41. Saha, S. & Raghava, G. P. S. BcePred: Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-chemical Properties. in Artificial Immune Systems (eds. Nicosia, G., Cutello, V., Bentley, P. J. & Timmis, J.) 197\u2013204 (Springer, Berlin, Heidelberg, 2004). https:\/\/doi.org\/10.1007\/978-3-540-30220-9_16.","DOI":"10.1007\/978-3-540-30220-9_16"},{"key":"74438_CR42","doi-asserted-by":"crossref","unstructured":"42. Dimitrov, I., Bangov, I., Flower, D. R. & Doytchinova, I. AllerTOP v.2\u2014a server for in silico prediction of allergens. J. Mol. Model. 20, 2278 (2014).","DOI":"10.1007\/s00894-014-2278-5"},{"key":"74438_CR43","doi-asserted-by":"crossref","unstructured":"43. Singh, H. & Raghava, G. P. S. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinforma. Oxf. Engl. 19, 1009\u20131014 (2003).","DOI":"10.1093\/bioinformatics\/btg108"},{"key":"74438_CR44","doi-asserted-by":"crossref","unstructured":"44. Doytchinova, I. A., Guan, P. & Flower, D. R. EpiJen: a server for multistep T cell epitope prediction. BMC Bioinformatics. 7, 131 (2006).","DOI":"10.1186\/1471-2105-7-131"},{"key":"74438_CR45","doi-asserted-by":"crossref","unstructured":"45. Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. Publ. Protein Soc. 12, 1007\u20131017 (2003).","DOI":"10.1110\/ps.0239403"},{"key":"74438_CR46","doi-asserted-by":"crossref","unstructured":"46. Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 32, 511\u2013517 (2016).","DOI":"10.1093\/bioinformatics\/btv639"},{"key":"74438_CR47","doi-asserted-by":"crossref","unstructured":"47. Larsen, M. V. et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 8, 424 (2007).","DOI":"10.1186\/1471-2105-8-424"},{"key":"74438_CR48","doi-asserted-by":"crossref","unstructured":"48. Jensen, K. K. et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 154, 394\u2013406 (2018).","DOI":"10.1111\/imm.12889"},{"key":"74438_CR49","doi-asserted-by":"crossref","unstructured":"49. Dhanda, S. K., Gupta, S., Vir, P. & Raghava, G. P. S. Prediction of IL4 inducing peptides. Clin. Dev. Immunol. 2013, 263952 (2013).","DOI":"10.1155\/2013\/263952"},{"key":"74438_CR50","doi-asserted-by":"crossref","unstructured":"50. Dhanda, S. K., Vir, P. & Raghava, G. P. Designing of interferon-gamma inducing MHC class-II binders. Biol. Direct. 8, 30 (2013).","DOI":"10.1186\/1745-6150-8-30"},{"key":"74438_CR51","doi-asserted-by":"crossref","unstructured":"51. Magnan, C. N. et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinforma. Oxf. Engl. 26, 2936\u20132943 (2010).","DOI":"10.1093\/bioinformatics\/btq551"},{"key":"74438_CR52","doi-asserted-by":"crossref","unstructured":"52. Saha, S. & Raghava, G. P. S. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 34, W202-209 (2006).","DOI":"10.1093\/nar\/gkl343"},{"key":"74438_CR53","doi-asserted-by":"crossref","unstructured":"53. Sippl, M. J. Recognition of errors in three-dimensional structures of proteins. Proteins. 17, 355\u2013362 (1993).","DOI":"10.1002\/prot.340170404"},{"key":"74438_CR54","doi-asserted-by":"crossref","unstructured":"54. Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407\u2013W410 (2007).","DOI":"10.1093\/nar\/gkm290"},{"key":"74438_CR55","doi-asserted-by":"crossref","unstructured":"55. Gao, J., Wang, Y., Liu, Z. & Wang, Z. Phage display and its application in vaccine design. Ann. Microbiol. 60, 13\u201319 (2010).","DOI":"10.1007\/s13213-009-0014-7"},{"key":"74438_CR56","doi-asserted-by":"crossref","unstructured":"56. Hashemi, H., Bamdad, T., Jamali, A., Pouyanfard, S. & Mohammadi, M. G. Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: A comparative approach to conventional DNA vaccine. J. Virol. Methods. 163, 440\u2013444 (2010).","DOI":"10.1016\/j.jviromet.2009.11.008"},{"key":"74438_CR57","doi-asserted-by":"crossref","unstructured":"57. Van Belleghem, J. D., D\u0105browska, K., Vaneechoutte, M., Barr, J. J. & Bollyky, P. L. Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System. Viruses. 11, 10 (2019).","DOI":"10.3390\/v11010010"},{"key":"74438_CR58","doi-asserted-by":"crossref","unstructured":"58. Fang, J. et al. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine. 23, 4860\u20134866 (2005).","DOI":"10.1016\/j.vaccine.2005.05.024"},{"key":"74438_CR59","doi-asserted-by":"crossref","unstructured":"59. Sartorius, R. et al. Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. EMBO Mol. Med. 7, 973\u2013988 (2015).","DOI":"10.15252\/emmm.201404525"},{"key":"74438_CR60","doi-asserted-by":"crossref","unstructured":"60. Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature. 520, 702\u2013705 (2015).","DOI":"10.1038\/nature14138"},{"key":"74438_CR61","doi-asserted-by":"crossref","unstructured":"61. Fukui, R. et al. Cleavage of Toll-Like Receptor 9 Ectodomain Is Required for In Vivo Responses to Single Strand DNA. Front. Immunol. 9, (2018).","DOI":"10.3389\/fimmu.2018.01491"},{"key":"74438_CR62","doi-asserted-by":"crossref","unstructured":"62. Ohto, U. et al. Toll-like Receptor 9 Contains Two DNA Binding Sites that Function Cooperatively to Promote Receptor Dimerization and Activation. Immunity. 48, 649\u2013658.e4 (2018).","DOI":"10.1016\/j.immuni.2018.03.013"},{"key":"74438_CR63","doi-asserted-by":"crossref","unstructured":"63. Ishida, H., Ohto, U., Shibata, T., Miyake, K. & Shimizu, T. Structural basis for species-specific activation of mouse Toll-like receptor 9. FEBS Lett. 592, 2636\u20132646 (2018).","DOI":"10.1002\/1873-3468.13176"},{"key":"74438_CR64","doi-asserted-by":"crossref","unstructured":"64. Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 1\u20132, 19\u201325 (2015).","DOI":"10.1016\/j.softx.2015.06.001"},{"key":"74438_CR65","doi-asserted-by":"crossref","unstructured":"65. Barkhordari, A., Mahnam, K. & Mirmohammad-Sadeghi, H. Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-\u03b1 and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis. J. Mol. Model. 26, 225 (2020).","DOI":"10.1007\/s00894-020-04510-5"},{"key":"74438_CR66","doi-asserted-by":"crossref","unstructured":"66. N\u00e9ron, B. et al. Mobyle: a new full web bioinformatics framework. Bioinforma. Oxf. Engl. 25, 3005\u20133011 (2009).","DOI":"10.1093\/bioinformatics\/btp493"},{"key":"74438_CR67","doi-asserted-by":"crossref","unstructured":"67. Alland, C. et al. RPBS: a web resource for structural bioinformatics. Nucleic Acids Res. 33, W44\u2013W49 (2005).","DOI":"10.1093\/nar\/gki477"},{"key":"74438_CR68","doi-asserted-by":"crossref","unstructured":"68. Li, S., Olson, W. K. & Lu, X.-J. Web 3DNA 2.0 for the analysis, visualization, and modeling of 3D nucleic acid structures. Nucleic Acids Res. 47, W26\u2013W34 (2019).","DOI":"10.1093\/nar\/gkz394"},{"key":"74438_CR69","doi-asserted-by":"crossref","unstructured":"69. Honorato, R. V. et al. Structural Biology in the Clouds: The WeNMR-EOSC Ecosystem. Front. Mol. Biosci. 8, 729513 (2021).","DOI":"10.3389\/fmolb.2021.729513"},{"key":"74438_CR70","doi-asserted-by":"crossref","unstructured":"70. van Zundert, G. C. P. et al. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. J. Mol. Biol. 428, 720\u2013725 (2016).","DOI":"10.1016\/j.jmb.2015.09.014"},{"key":"74438_CR71","doi-asserted-by":"crossref","unstructured":"71. Kumari, R., Kumar, R., Open Source Drug Discovery Consortium & Lynn, A. g_mmpbsa\u2013a GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 54, 1951\u20131962 (2014).","DOI":"10.1021\/ci500020m"},{"key":"74438_CR72","doi-asserted-by":"crossref","unstructured":"72. Padilla-Quirarte, H. O., Lopez-Guerrero, D. V., Gutierrez-Xicotencatl, L. & Esquivel-Guadarrama, F. Protective Antibodies Against Influenza Proteins. Front. Immunol. 10, 1677 (2019).","DOI":"10.3389\/fimmu.2019.01677"},{"key":"74438_CR73","doi-asserted-by":"crossref","unstructured":"73. Paules, C. I., Sullivan, S. G., Subbarao, K. & Fauci, A. S. Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine. N. Engl. J. Med. 378, 7\u20139 (2018).","DOI":"10.1056\/NEJMp1714916"},{"key":"74438_CR74","doi-asserted-by":"crossref","unstructured":"74. Raymond, D. D. et al. Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc. Natl. Acad. Sci. 115, 168\u2013173 (2018).","DOI":"10.1073\/pnas.1715471115"},{"key":"74438_CR75","doi-asserted-by":"crossref","unstructured":"75. Joyce, M. G. et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 166, 609\u2013623 (2016).","DOI":"10.1016\/j.cell.2016.06.043"},{"key":"74438_CR76","doi-asserted-by":"crossref","unstructured":"76. Zalewska-Pi\u0105tek, B. & Pi\u0105tek, R. Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development. Pharmaceuticals. 14, 331 (2021).","DOI":"10.3390\/ph14040331"},{"key":"74438_CR77","doi-asserted-by":"crossref","unstructured":"77. Gupta, N. & Kumar, A. Designing an efficient multi-epitope vaccine against Campylobacter jejuni using immunoinformatics and reverse vaccinology approach. Microb. Pathog. 147, 104398 (2020).","DOI":"10.1016\/j.micpath.2020.104398"},{"key":"74438_CR78","doi-asserted-by":"crossref","unstructured":"78. Forouharmehr, A. Engineering an efficient poly-epitope vaccine against Toxoplasma gondii infection: A computational vaccinology study. Microb. Pathog. 152, 104646 (2021).","DOI":"10.1016\/j.micpath.2020.104646"},{"key":"74438_CR79","doi-asserted-by":"crossref","unstructured":"79. Tahir ul Qamar, M. et al. Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches. Comput. Biol. Med. 132, 104389 (2021).","DOI":"10.1016\/j.compbiomed.2021.104389"},{"key":"74438_CR80","doi-asserted-by":"crossref","unstructured":"80. Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A. & Ghahremani, F. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine. 38, 7612\u20137628 (2020).","DOI":"10.1016\/j.vaccine.2020.10.016"},{"key":"74438_CR81","doi-asserted-by":"crossref","unstructured":"81. Sanami, S. et al. Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study. Comput. Biol. Med. 133, 104390 (2021).","DOI":"10.1016\/j.compbiomed.2021.104390"},{"key":"74438_CR82","doi-asserted-by":"crossref","unstructured":"82. Bao, Q. et al. Phage-based vaccines. Adv. Drug Deliv. Rev. 145, 40\u201356 (2019).","DOI":"10.1016\/j.addr.2018.12.013"},{"key":"74438_CR83","doi-asserted-by":"crossref","unstructured":"83. Hess, K. L. & Jewell, C. M. Phage display as a tool for vaccine and immunotherapy development. Bioeng. Transl. Med. 5, e10142 (2019).","DOI":"10.1002\/btm2.10142"},{"key":"74438_CR84","doi-asserted-by":"crossref","unstructured":"84. Iwagami, Y. et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 3, e00407 (2017).","DOI":"10.1016\/j.heliyon.2017.e00407"},{"key":"74438_CR85","doi-asserted-by":"crossref","unstructured":"85. Morales, J. et al. Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine. 26, 2899\u20132905 (2008).","DOI":"10.1016\/j.vaccine.2008.03.042"},{"key":"74438_CR86","doi-asserted-by":"crossref","unstructured":"86. Bastien, N., Trudel, M. & Simard, C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology. 234, 118\u2013122 (1997).","DOI":"10.1006\/viro.1997.8632"},{"key":"74438_CR87","doi-asserted-by":"crossref","unstructured":"87. Wan, Y. et al. Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine. Vaccine. 19, 2918\u20132923 (2001).","DOI":"10.1016\/S0264-410X(00)00561-2"},{"key":"74438_CR88","doi-asserted-by":"crossref","unstructured":"88. Stoloff, G. A. & Caparros-Wanderley, W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur. J. Immunol. 37, 2441\u20132449 (2007).","DOI":"10.1002\/eji.200737254"},{"key":"74438_CR89","doi-asserted-by":"crossref","unstructured":"89. Stanekov\u00e1, Z. & Vare\u010dkov\u00e1, E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 7, 351 (2010).","DOI":"10.1186\/1743-422X-7-351"},{"key":"74438_CR90","doi-asserted-by":"crossref","unstructured":"90. Maleki, A., Russo, G., Parasiliti Palumbo, G. A. & Pappalardo, F. In silico design of recombinant multi-epitope vaccine against influenza A virus. BMC Bioinformatics. 22, 617 (2022).","DOI":"10.1186\/s12859-022-04581-6"},{"key":"74438_CR91","doi-asserted-by":"crossref","unstructured":"91. Kanse, S. et al. Designing a Multi-Epitope Subunit Vaccine against VP1 Major Coat Protein of JC Polyomavirus. Vaccines. 11, 1182 (2023).","DOI":"10.3390\/vaccines11071182"},{"key":"74438_CR92","doi-asserted-by":"crossref","unstructured":"92. Jiang, F. et al. PP19128R, a Multiepitope Vaccine Designed to Prevent Latent Tuberculosis Infection, Induced Immune Responses In Silico and In Vitro Assays. Vaccines. 11, 856 (2023).","DOI":"10.3390\/vaccines11040856"},{"key":"74438_CR93","doi-asserted-by":"crossref","unstructured":"93. Khamjan, N. A., Lohani, M., Khan, M. F., Khan, S. & Algaissi, A. Immunoinformatics Strategy to Develop a Novel Universal Multiple Epitope-Based COVID-19 Vaccine. Vaccines. 11, 1090 (2023).","DOI":"10.3390\/vaccines11061090"},{"key":"74438_CR94","doi-asserted-by":"crossref","unstructured":"94. Wilkins, M. R. et al. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. Clifton NJ. 112, 531\u2013552 (1999).","DOI":"10.1385\/1-59259-584-7:531"},{"key":"74438_CR95","doi-asserted-by":"crossref","unstructured":"95. Sarkar, B., Ullah, M. A. & Araf, Y. A systematic and reverse vaccinology approach to design novel subunit vaccines against Dengue virus type-1 (DENV-1) and human Papillomavirus-16 (HPV-16). Inform. Med. Unlocked. 19, 100343 (2020).","DOI":"10.1016\/j.imu.2020.100343"},{"key":"74438_CR96","doi-asserted-by":"crossref","unstructured":"96. Ashfaq, U. A. et al. Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach. PloS ONE. 16, e0245072 (2021).","DOI":"10.1371\/journal.pone.0245072"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74438-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74438-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74438-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:11:56Z","timestamp":1729847516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74438-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74438"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74438-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25382"}}